Clinical trials have demonstrated promising efficacy of HER3-DXd in EGFR-mutant NSCLC patients who have developed resistance to tyrosine kinase inhibitors (TKIs), thus highlighting its potential as a novel therapeutic option [46]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.